Vertex Pharmaceuticals Incorporated (FRA:VX1)
Germany · Delayed Price · Currency is EUR 396.15
-1.25 (-0.31%)
At close: Jan 30, 2026
Vertex Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 11,693 | 11,020 | 9,869 | 8,931 | 7,573 | 6,203 |
Other Revenue | 30.7 | - | - | - | 1 | 2.9 |
| 11,723 | 11,020 | 9,869 | 8,931 | 7,574 | 6,206 | |
Revenue Growth (YoY) | 10.33% | 11.66% | 10.51% | 17.91% | 22.06% | 49.08% |
Cost of Revenue | 5,543 | 5,161 | 4,425 | 3,608 | 2,842 | 2,381 |
Gross Profit | 6,180 | 5,859 | 5,444 | 5,323 | 4,732 | 3,825 |
Selling, General & Admin | 1,644 | 1,464 | 1,137 | 944.7 | 840.1 | 770.5 |
Operating Expenses | 1,644 | 1,464 | 1,137 | 944.7 | 840.1 | 770.5 |
Operating Income | 4,536 | 4,395 | 4,308 | 4,378 | 3,892 | 3,054 |
Interest Expense | -12.8 | -30.6 | -44.1 | -54.8 | -61.5 | -58.2 |
Interest & Investment Income | 497.2 | 598.1 | 614.7 | 144.6 | 4.9 | 22.2 |
Currency Exchange Gain (Loss) | -38.8 | -27.3 | -24.6 | -15.1 | -13.9 | -16.1 |
Other Non Operating Income (Expenses) | 25.2 | -49.3 | 9.3 | -0.6 | 1.7 | 0.8 |
EBT Excluding Unusual Items | 5,007 | 4,886 | 4,863 | 4,453 | 3,824 | 3,003 |
Gain (Loss) on Sale of Investments | -15.5 | -9.5 | -7.5 | -149.1 | 17.1 | 311.9 |
Asset Writedown | -379 | - | - | -13 | - | - |
Other Unusual Items | - | 0.5 | 51.6 | 57.5 | 3.1 | -13.1 |
Pretax Income | 4,449 | 248.5 | 4,380 | 4,232 | 2,730 | 3,117 |
Income Tax Expense | 773.6 | 784.1 | 760.2 | 910.4 | 388.3 | 405.2 |
Earnings From Continuing Operations | 3,675 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 |
Net Income to Company | 3,675 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 |
Net Income | 3,675 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 |
Net Income to Common | 3,675 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 |
Net Income Growth | - | - | 8.96% | 41.84% | -13.63% | 130.43% |
Shares Outstanding (Basic) | 257 | 258 | 258 | 256 | 258 | 260 |
Shares Outstanding (Diluted) | 258 | 258 | 261 | 259 | 260 | 263 |
Shares Change (YoY) | 0.11% | -1.00% | 0.54% | -0.31% | -1.33% | 1.04% |
EPS (Basic) | 14.32 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 |
EPS (Diluted) | 14.22 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 |
EPS Growth | - | - | 8.35% | 42.29% | -12.44% | 128.16% |
Free Cash Flow | 3,337 | -790.3 | 3,337 | 3,925 | 2,409 | 2,994 |
Free Cash Flow Per Share | 12.92 | -3.06 | 12.81 | 15.15 | 9.27 | 11.37 |
Gross Margin | 52.72% | 53.17% | 55.16% | 59.60% | 62.48% | 61.63% |
Operating Margin | 38.70% | 39.88% | 43.65% | 49.03% | 51.39% | 49.21% |
Profit Margin | 31.35% | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% |
Free Cash Flow Margin | 28.47% | -7.17% | 33.81% | 43.95% | 31.80% | 48.24% |
EBITDA | 4,712 | 4,577 | 4,477 | 4,527 | 4,018 | 3,164 |
EBITDA Margin | 40.19% | 41.53% | 45.36% | 50.69% | 53.05% | 50.98% |
D&A For EBITDA | 175.4 | 182 | 169.5 | 148.3 | 125.6 | 109.5 |
EBIT | 4,536 | 4,395 | 4,308 | 4,378 | 3,892 | 3,054 |
EBIT Margin | 38.70% | 39.88% | 43.65% | 49.03% | 51.39% | 49.21% |
Effective Tax Rate | 17.39% | 315.53% | 17.36% | 21.51% | 14.22% | 13.00% |
Revenue as Reported | 703.2 | - | - | - | 7,574 | 6,206 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.